Jaguar Health Future Growth
Future criteria checks 2/6
Jaguar Health is forecast to grow earnings and revenue by 25.9% and 34.8% per annum respectively while EPS is expected to grow by 66.4% per annum.
Key information
25.9%
Earnings growth rate
66.4%
EPS growth rate
| Pharmaceuticals earnings growth | 23.9% |
| Revenue growth rate | 34.8% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 19 Nov 2024 |
Recent future growth updates
Recent updates
Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 27%
Nov 09
Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 27%
Nov 09Jaguar Health, Inc. (NASDAQ:JAGX) Stock's 55% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Jul 24Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 49%
May 24Jaguar Health, Inc. (NASDAQ:JAGX) Shares Fly 55% But Investors Aren't Buying For Growth
Mar 29Jaguar Health, Inc. (NASDAQ:JAGX) Not Doing Enough For Some Investors As Its Shares Slump 39%
Jan 22Positive Sentiment Still Eludes Jaguar Health, Inc. (NASDAQ:JAGX) Following 32% Share Price Slump
Jun 10Jaguar Health (NASDAQ:JAGX) Is Carrying A Fair Bit Of Debt
Jan 23Jaguar Health rises 19% on orphan drug tag for congenital diarrheal disorder treatment
Oct 17Jaguar Health sells crofelemer and lechlemer royalty rights for $4M upfront
Aug 25Jaguar Health gets 180-day grace period to regain compliance with Nasdaq's listing rule
Aug 19Jaguar Health rises on U.S. patent for treating chemotherapy-induced diarrhea
Aug 09Jaguar stock rises on license deal with SynWorld for Canalevia in China
Jun 29Jaguar Health CEO Lisa Conte - From Rainforest To Laboratory
Mar 07Jaguar Health shares jumps 13% after pricing $15M direct offering
Jan 13Jaguar Health plans for conditional marketing application in Europe for Crofelemer, initially for Long-Hauler COVID-19 patients
Jan 11Jaguar Health leaps higher in new year
Jan 05Jaguar Health inks second Mytesi royalties agreement for $6M
Dec 23Does Jaguar Health (NASDAQ:JAGX) Have A Healthy Balance Sheet?
Dec 02
Jaguar Health's crofelemer development nears SPAC funding in Europe, shares +61%
Nov 30Jaguar Health EPS misses by $0.10, misses on revenue
Nov 16Jaguar Health receives positive Nasdaq listing determination
Oct 29Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 22 | -20 | N/A | -25 | 1 |
| 12/31/2025 | 16 | -27 | N/A | -24 | 1 |
| 12/31/2024 | 11 | -36 | N/A | -26 | 1 |
| 9/30/2024 | 10 | -38 | -29 | -29 | N/A |
| 6/30/2024 | 10 | -36 | -29 | -29 | N/A |
| 3/31/2024 | 10 | -38 | -30 | -30 | N/A |
| 12/31/2023 | 10 | -41 | -33 | -33 | N/A |
| 9/30/2023 | 11 | -40 | -33 | -32 | N/A |
| 6/30/2023 | 11 | -44 | -34 | -34 | N/A |
| 3/31/2023 | 11 | -42 | -37 | -35 | N/A |
| 12/31/2022 | 12 | -47 | -35 | -33 | N/A |
| 9/30/2022 | 11 | -54 | -37 | -36 | N/A |
| 6/30/2022 | 8 | -54 | -38 | -37 | N/A |
| 3/31/2022 | 6 | -59 | -36 | -36 | N/A |
| 12/31/2021 | 4 | -53 | -35 | -35 | N/A |
| 9/30/2021 | 5 | -50 | -30 | -30 | N/A |
| 6/30/2021 | 7 | -46 | -24 | -24 | N/A |
| 3/31/2021 | 10 | -42 | -18 | -18 | N/A |
| 12/31/2020 | 9 | -39 | -15 | -15 | N/A |
| 9/30/2020 | 8 | -35 | -14 | -14 | N/A |
| 6/30/2020 | 7 | -39 | -20 | -20 | N/A |
| 3/31/2020 | 5 | -45 | -21 | -21 | N/A |
| 12/31/2019 | 6 | -45 | -20 | -20 | N/A |
| 9/30/2019 | 6 | -48 | -22 | -22 | N/A |
| 6/30/2019 | 6 | -43 | -16 | -16 | N/A |
| 3/31/2019 | 5 | -34 | -17 | -17 | N/A |
| 12/31/2018 | 4 | -32 | -23 | -23 | N/A |
| 9/30/2018 | 4 | -41 | -23 | -23 | N/A |
| 6/30/2018 | 4 | -30 | N/A | -23 | N/A |
| 3/31/2018 | 4 | -24 | N/A | -19 | N/A |
| 12/31/2017 | 4 | -22 | N/A | -10 | N/A |
| 9/30/2017 | 3 | -5 | N/A | -7 | N/A |
| 6/30/2017 | 2 | -14 | N/A | -17 | N/A |
| 3/31/2017 | 1 | -17 | N/A | -15 | N/A |
| 12/31/2016 | 0 | -15 | N/A | -14 | N/A |
| 12/31/2015 | 0 | 5 | N/A | 1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: JAGX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: JAGX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: JAGX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: JAGX's revenue (34.8% per year) is forecast to grow faster than the US market (9.1% per year).
High Growth Revenue: JAGX's revenue (34.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if JAGX's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 08:12 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Jaguar Health, Inc. is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert LeBoyer | Aegis Capital Corporation |
| Louise Chen | Cantor Fitzgerald & Co. |
| Vernon Bernardino | H.C. Wainwright & Co. |